Gyre Therapeutics(NASDAQ) GYRE

Gyre Therapeutics helps people with organ scarring and swelling. These medicines slow down damage to the lungs and liver. The company sells treatments in China and studies new drugs.

Medicines for Damaged Organs

• ETUARY: Pill used to treat lung scarring, a disease where lung tissue thickens and scars over time.
• Etorel: Capsule used as a standard treatment for lung scarring and related lung diseases.
• Contiva: Tablet that treats low blood platelet counts for patients with liver disease.
• Development Pipeline: Research programs focused on liver scarring, chronic pain, and various types of cancer.

New Pipelines and Partnerships

• Acquired Cullgen in May 2026 to add protein degradation technology for pain and cancer treatments.
• Submitted an application for F351 to treat liver scarring in China during March 2026.
• Began selling Etorel in the China market in June 2025.
• Started commercial sales of Contiva for liver-related blood issues in March 2025.

A Focus on Targeted Degradation

Gyre maintains a dual operation with commercial sales in China and clinical development in San Diego. The company uses targeted protein degraders, which are designed to remove specific harmful proteins from a patient's body.

A Look at the Finances

• Revenue was $29.1 million for the three-month period ended June 30, 2026, down 2% year over year.
• Net loss reached $32.8 million for the six-month period ended June 30, 2026.
• Research and development costs rose 129% year over year to $19.1 million for the three-month period ended June 30, 2026.
• Cash and cash equivalents were $43.3 million as of June 30, 2026.

Moving Beyond Fibrosis

Gyre has shifted from focusing only on lung scarring to developing a wide range of therapies for liver disease, pain, and cancer. Its recent acquisition and clinical progress in China have expanded its reach across multiple medical fields.